This guide provides corporate counsel and international practitioners with comprehensive jurisdiction-by-jurisdiction guidance to digital health laws and regulations around the world.
Topics covered include digital health technologies, data use, data sharing, intellectual property, commercial agreements, AI and machine learning, and liability.
In this multi-jurisdictional guide, explore an overview of key legal issues, rules and developments regarding pharmaceutical advertising across a range of jurisdictions.
This guide provides a compilation of insights from legal practitioners around the world to assist in the identification and understanding of the laws and regulations that impact the drug and medical device industry.
On April 23, 2024, the U.S. Federal Trade Commission finalized a rule, by a vote of 3-2, abolishing the vast majority of employee covenants not to compete across the United States.
While certain health care providers will be exempted from the rule, many will not. As such, and if the rule survives legal challenge, health care industry participants should carefully consider how the rule will impact their recruitment and retention strategies going forward.
Read about the Implications for in-house counsel of the US Supreme Court's decision in Dobbs v. Jackson Women's Health Organization in a selection of resources.
The intersection of software, technology and health care and the proliferation of software as a medical device in the health care arena has become common place and has spurred significant innovations. This article discusses legal and regulatory considerations related to Software as a Medical Device (SaMD).
This Top Ten article discusses government enforcement-related updates impacting the health care industry in the United States.
Check out this whitepaper developed by Foley & Lardner LLP to learn more about the top twelve trends in the digital assets space.
Learn more about the new Special Fraud Alert published by the Office of Inspector General, U.S. Department of Health and Human Services on arrangements with telemedicine companies, setting forth seven characteristics OIG believes could suggest a given arrangement poses a heighted risk of fraud and abuse.
Patented medicine regulations in Canada can be complex and the review process is fast-paced. In this Top Ten, in-house counsel will learn the essential points of how to prepare for the "Regulations" review. Editor's note: This article was updated to reflect recent developments; a prior version of this article was published on August 6, 2020.